Infant Bacterial Therapeutics
54
SEK
-8.47 %
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-8.47%
+41.36%
+54.73%
-45.23%
-40%
-40.13%
-11.48%
-60.98%
-7.64%
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Read moreMarket cap
727.46M SEK
Turnover
1.88M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
13.2
2025
Annual report '24
7.5
2025
Interim report Q1'25
8.5
2025
General meeting '24
ShowingAll content types
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
Infant Bacterial Therapeutics to present at FDA workshop in the USA
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools